All News

RheumNow Podcast square

EULAR 2026 Rheumatology RoundUp

Jack Cush, MD

It’s time for Rheumatology RoundUp from EULAR 2026 from London, UK. Drs. Artie Kavanaugh and Jack Cush review their choice presentations from the meeting, offering their perspectives on impact and applicability.

Read Article
laptop

LLMs in SLE: From Patient Education to Clinical Decision Support

Bella Mehta, MBBS, MS

The emergence of large language models (LLMs) represents a promising shift in how complex diseases such as systemic lupus erythematosus (SLE) are communicated and interpreted across both patient and clinical settings. Two EULAR 2026 abstracts highlight the evolving role of LLMs across this spectrum, from patient-facing education to diagnostic reasoning.

Read Article
EULAR meeting room

NK Cells Without a CAR: AB-101 Is Neither CAR-T nor CAR-NK

Henrique Dalmolin, MD

Much of the meeting came for the next CAR T readout. AB-101 drew attention for a different reason. It depletes B cells by a completely different route.

Read Article
menopause on scrabble tiles

Hot topic: menopause and inflammatory arthritis outcomes in RA and PsA

Aurelie Najm, MD, PhD

Across EULAR 2026 abstracts this year and presented in a session called “this is a woman’s world”, strong signals are emerging that the menopausal transition is associated with changes in disease phenotype, disease activity, and treatment response in both RA and PsA.

Read Article

“Science is organized knowledge. Wisdom is organized life.” - Immanuel Kant

Dr. John Cush RheumNow ( View Tweet)

Vasculitis Updates: Glucocorticoid use in AAV and GCA Vasculitis Updates: Glucocorticoids are the cornerstone of initial therapy for AAV and GCA—quickly reducing inflammation and preserving organs. EULAR has issued recommendations on glucocorticoid use in ANCA‑associated and https://t.co/hIOKyXDxyb
Dr. John Cush RheumNow ( View Tweet)
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London. https://t.co/ir9pdwBnH4 https://t.co/yjjgcA2TRv

Links:

Dr. John Cush RheumNow ( View Tweet)
PsA Topic Panel: EULAR 2026 Join Drs. Jack Cush, Peter Nash, Antoni Chan, and Nelly Ziade for an expert discussion on the most important psoriatic arthritis developments emerging from EULAR 2026. Abstracts discuss: OP0187, OP069, LB0001, POS0668, OP071 https://t.co/S7Fz5YR3V0 https://t.co/treaJ1OzwB

Links:

Dr. John Cush RheumNow ( View Tweet)
Exploring Idiopathic Myopathies #EULAR2026: Idiopathic inflammatory myopathies (IIM) are a diverse group of autoimmune diseases with significant morbidity. While EULAR/ACR classification criteria were established in 2017, updated real-world data and better tools to assess https://t.co/CbUWodWT7z
Dr. John Cush RheumNow ( View Tweet)
Digital Platforms and AI Work was presented from three PARE initiatives that showcase how digital tools can be used in treatment education and decision-making, and potentially avoid the use of general web searches to answer important questions. https://t.co/LxXeFdAbU7 https://t.co/ocqSBhYHEf

Links:

Dr. John Cush RheumNow ( View Tweet)
Understanding Comorbidities in RMD People with rheumatic and musculoskeletal diseases (RMD) are at risk of a number of comorbidities, from cardiovascular diseases to cognitive impairment and fractures. EIULAR 2026 showcased new data and ideas around various comorbidities and https://t.co/twr0EiMp9f
Dr. John Cush RheumNow ( View Tweet)
All content is independently chosen and produced by the RheumNow faculty. RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB.

Dr. John Cush RheumNow ( View Tweet)

Day 1 Report from EULAR 2026 The first day of EULAR 2026 in London featured the opening ceremonies, a plenary session, posters nd the first round of major oral presentations to an audience of nearly 15,000 attendees. Here are a few of my favorites from the first day. https://t.co/qCnoiGedat
Dr. John Cush RheumNow ( View Tweet)
#EULAR2026 Want to catch up with the latest breakthrough in research on the last day of the conference? Please find our Day 4 Daily Recap led by @RheumNow and joined by my colleagues @synovialjoints @DrMiniDey 😃 https://t.co/fONe6g4ne1 https://t.co/kOqzF8t64w

Links:

Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
RheumNow’s expanded coverage of the #EULAR2026 Annual Meeting is sponsored by Bristol Myers Squibb and UCB. RheumNow and its faculty independently select all coverage content.

Dr. John Cush RheumNow ( View Tweet)

Some new #vaccination #recommendations #EULAR2026 @RheumNow https://t.co/j7cOJPpOcV https://t.co/VnGkFwTZ86

Links:

Janet Pope Janetbirdope ( View Tweet)
Remember Babies of pts on chronic #immunosuppression with #SARDs ❎delay #vaccinations til 6/12 For safety & to mount sufficient response #rotovirus #vaccine is Ok before 6 months or vaccine is ineffective Pts w #SARDs need #COVID shots @RheumNow #EULAR2026 #vaccine #recom https://t.co/WEzNajWlxY

Links:

Janet Pope Janetbirdope ( View Tweet)
What’s new with the 2026 update of reco for vax in AIIRD? Vaccinate as soon as possible Non-live vaccines are safe Hold MTX for upto 2wks to inc vax yield Strong reco for RZV Catch-up vax for HPV in SLE Rotavirus vax for newborns exposed in utero to TNFi @RheumNow #EULAR2026 https://t.co/RZbyvAcYRI

Links:

sheila RHEUMarampa ( View Tweet)
#EULAR2026 #SARD #vaccination #recommendations I think 🤔 ✅proactive➡️take responsibility ✅close gap ✅mostly practical But How long will #shingrix work if #vaccine In age<50yrs When if ever To revaccinate? @RheumNow @eular_org @ACRheum https://t.co/najJwzdecL

Links:

Janet Pope Janetbirdope ( View Tweet)
Good performance of #definite #antisynthetase #syndrome ✅+antibody mandatory Possible also does ok @RheumNow #EULAR2026 June 6 #antisynthetase #classifiaction #criteria https://t.co/5sxogTX9YT

Links:

Janet Pope Janetbirdope ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×